Resveratrol Ingredient Linked to French Paradox in Humans

Kaiseraugst, SwitzerlandNutrition, Metabolism & Cardiovascular Diseases printed what is being called the first published human study that shows resveratrol supplementation offers the heart health benefits of the French Paradox.

In research conducted at the University of South Australia on a branded ingredient (resVida from DSM, headquartered here), scientists found that the ingredient increased flow-mediated dilation (FMD) of the brachial artery. According to the group, this is “a biomarker of endothelial function and cardiovascular health.”

Nineteen overweight men and women with borderline high blood pressure participated in the trial. None of them were being treating for hypertension. The group were given a placebo and various doses of resveratrol (30, 90 or 270 mg) at weekly intervals, and their FMD and resveratrol serum levels were checked after an hour. Comparing these factors from taking the placebo to the 270-mg dose, researchers found that resveratrol levels increased as did FMD (from about 4.1 to about 7.7).

The group noted, “This effect may contribute to the purported cardiovascular health benefits of grapes and red wine.”

Published in WholeFoods Magazine, November 2010 (published ahead of print September 24, 2010)